Dr. Feuerstein received his MD (medicine) and MSc (Pharmacology) from the Hebrew University Jerusalem Israel. He proceeded
to complete a Fellowship at the NIH (Bethesda MD, USA) in the laboratories of clinical sciences Dr Feuerstein proceeded
with academic career at USUHS, Bethesda Md where he served as Prof. and Head of the neurobiology labs. Since
1988-2010 Dr Feuerstein career diverted his career with the Pharmaceutical sector (GSK, BMS, and Wyeth/Pfizer). He is
acknowledged for leadership in the development of carvedilol (heart failure), Eliquis and anti-FIX, hemostasis), endothelin
and angiotensin antagonists. Dr Feuerstein main areas of expertise include hemostasis, cardiovascular disease, stroke,
and inflammation. In the position of VP of Discovery translational medicine, (Wyeth/Pfizer) he generated new paradigms
for drug discovery based on genomic and biomarkers. Dr Feuerstein has over 700 publication and 440 basic research
papers. Dr Feuerstein received National and International awards and holds 18 patents (issues and pending). Currently
Dr Feuerstein serves as Chief Science and Medicine at Debina Diagnostic Inc, a Nanomedicine and nanotechnology-
based company.

The art of drug discovery and development in a complex multi-disciplinary process that frequently extends over 10-15 years
at an expense of $1-1.5 Billion. The process of modern drug discovery favors target identity to which pharmacological manipulation
are designed to modify the target functions (in whichever direction) to ultimately garner medical benefits patients.
The complexities of this saga in most cases are not successful; in fact, 90% of early discovery programs fail of which
50% after clinical studies commenced.
The art of Pharmacology is core activity in this complex process. Commencing in the early discovery phase (once a compound/
biological is realized) pharmacology is the primary discipline that holds the fate of the success or demise of the
program at large. The reasons for this is that the pharmacology profile of the compounds generated in the preclinical domains
are done in conditions of little congruency to those that exists in humans even if the target itself is qualified for
medical development. In particular, parameters that define the compound-target interactions are invariably artificial and
therefore the pharmacodynamic consequences often remote from the targeted product profile (TPT) needed for clinical
and commercial successful drug.
The presentation today is aimed to detail strategies and actions that could significantly alleviates the translational risks
by using pharmacodynamic parameters and biomarkers for successful compounds selection. 3 different principles will be
discussed. A. the formula

Roman Manetsch received his PhD degree in 2002 from the University of Basel (Switzerland) working on catalytic antibodies
with Professor Wolf-Dietrich Woggon and Professor Jean-Louis Reymond (University of Bern, Switzerland). After a
postdoctoral experience with Professor K. Barry Sharpless investigating click chemistry applications at the Scripps Research
Institute in La Jolla (CA, USA), he started his independent career as an Assistant Professor at the Department of
Chemistry at the University of South Florida (Tampa, Florida). In 2014, Associate Professor Manetsch moved to the De
partment of Chemistry and Chemical Biology and the Department of Pharmaceutical Sciences at Northeastern University
(Boston, Massachusetts). His research focuses on the development of fragment-based lead discovery strategies, the development
of bio-orthogonal chemical probes for the study of specific proteins in complex biological matrices, as well as
hit-to-lead optimizations of antimalarial, antileishmanial, antibacterial, and antiamoebic agents.

The Manetsch laboratory focuses on the development and implementation of LC/MS-guided synthetic and medicinal
chemistry approaches for the identification and optimization of antiinfective agents. This presentation focuses on the
development of orally bioavailable antimalarial agents and their optimization into preclinical candidates. For approximately
half a century, endochin and analogues thereof were known to be causal prophylactic and potent erythrocytic
stage agents in avian but not in mammalian malaria models. Our hit-to-lead optimization efforts lead to orally bioavailable
4(1H)-quinolones with antimalarial activity against erythrocytic and exoerythrocytic stages. One of these compounds
advanced to preclinical evaluations, nevertheless it was not further developed due to limited aqueous solubility.[1]
Herein, we disclose a general prodrug approach that converts promising lead compounds into aminoalkoxycarbonyloxymethyl
(amino AOCOM) ether-substituted analogues that display significantly improved aqueous solubility and
enhanced oral bioavailability, restoring key requirements typical for drug candidate profiles.[2] The prodrug is completely
independent of biotransformations and it is animal-independent because it activates via a pH-triggered intramolecular
cyclization-elimination reaction. As a proof-of-concept, the utility of this novel amino AOCOM ether prodrug approach
was demonstrated on our antimalarial 4(1H)-quinolones, which entered and failed preclinical development over the last
decade. With the amino AOCOM ether prodrug moiety, 3-aryl-4(1H)-quinolone preclinical candidate was shown to provide
single-dose cures in a rodent malaria model at an oral dose of 3 mg/kg, without the use of an advanced formulation
technique.
References:
[1] Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE,
Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R,
Sinden RE, Kocken CHM, Price RN, Avery VM, Angulo-Barturen I, Jiménez-Díaz MB, Ferrer S, Herreros E, Sanz LM, Gamo
FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK. Quinolone-
3-diarylethers: a new class of antimalarial drug. Sci Transl Med 2013 Mar 20;5(177):177ra37.
[2] Monastyrskyi A, Brockmeyer F, LaCrue AN, Zhao Y, Maher SP, Maignan JR, Padin-Irizarry V, Sakhno YI, Parvatkar PT,
Asakawa AH, Huang L, Casandra D, Mashkouri S, Kyle DE, Manetsch R. Aminoalkoxycarbonyloxymethyl Ether Prodrugs
with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial
4(1H)-Quinolones with Single Dose Cures. J Med Chem 2021; 64(10): 6581-6595.

Dr Taghrid Istivan an associate professor at RMIT University, Melbourne, Australia. She is a medical microbiologist with
a PhD in molecular microbiology and over 20 years of research experience in investigating bacterial pathogenesis, and developing
novel therapeutics. The outcomes of her research have been published in reputable peer reviewed journals, book
chapters and were valuably cited by other international researchers. As the team leader of the pathogens and therapies
research group, and through multidisciplinary research collaboration, Dr. Istivan’s current research is focused on developing
novel peptide therapeutics, and drug delivery systems. Her team’s recent research findings are under IP protection to
enable future collaboration with pharmaceutical entities to develop reliable, cost-effective treatments for challenging infectious
diseases.

Peptide-based pharmacology active compounds are promising therapeutics for challenging health conditions and diseases.
In the past two decades, small molecular weight peptides have emerged as potential antimicrobials, anti-inflammatory,
and anticancer therapeutics due to their affordable in silico design and synthesis, in addition to their high specificity with
least adverse effects, and the readily intake by targeted cells. However, poor luminal permeability, high cytosolic metabolism,
gastric degradation and first hepatic clearance of these peptide therapies have resulted in low bioavailability. Hence,
the oral delivery of antimicrobial peptides is a great challenge due to the harsh gastric acidic conditions, low transepithelial
permeability, and the ubiquitous distribution of various proteinases and peptidase in the gastrointestinal tract. In this
talk, I will present our research on developing novel de novo designed peptides which mimic the activity of known biological
protein molecules as potential anticancer and/or antimicrobial therapeutics. Furthermore, I will highlight our recent
findings towards developing an oral formulation of a peptide delivery vehicle that meets the above-mentioned challenges.
Throughout the present research we have developed an oral slow-released drug delivery system based on biodegradable
hydrophilic hydroxypropyl methylcellulose (HPMC) biopolymer which was crosslinked with acrylic acid to produce a pH responsive
solid vehicle, and proved to responsively release its packaged cargo with no harmful effects on human epithelial
cells. The controlled slow release of the packaged peptide and its biological antimicrobial effect against known bacterial
pathogens were assessed in vitro, and our data showed that this drug delivery system protected the desired function of
the therapeutic peptide and provided a 48-hour continuous controlled release of its cargo

Dr. Sarojini received her PhD from the University of Kerala, India. She obtained her post-doctoral training at Gheens
Center for Aging, University of Louisville, KY in Biochemistry and Molecular biology. Dr. Sarojini joined the VitaSolTM research
group in 2011 at the University of Louisville to elucidate the cellular mechanisms behind the faster wound healing.
She has received several awards for her research contributions, including the Wound Healing Researcher Scholarship. Dr.
Sarojini is currently studying the molecular mechanisms responsible for faster wound healing and is the Principal Investigator
of the diabetic wound healing project in University of Louisville School of Medicine

To enhance incisional wound healing to reduce surgical wound dehiscence we use a newly developed intracellular ATP delivery
method. New Zealand white rabbits (35 adults) were used. On the back side of the body skin incisions were made
and closed. For one side of wounds ATP-vesicles mixed with a neutral cream was used for another side of the wounds the
neutral cream alone was used as a control. After 7 and 14 days’ post-surgery and treatment Laser speckle contrast imaging
(LSCI), biomechanical, histological, and immunohistochemical analyses were performed. In vitro macrophage culture
was used to assess the enhanced collagen production. 10 rabbits were used for wound perfusion study and 25 were used
for wound biomechanical and histological/immunohistochemical studies. During early days of post-surgery wound tissue
perfusion was reduced. But the biomechanical strength of the wound tissue was much higher in the ATP-vesicle treated
group than in the control treated group. Similar to our excisional wounds, healing was accompanied by earlier macrophage
accumulation, in situ proliferation, and direct collagen production. The results of direct collagen production are con
firmed by in vitro macrophage experiments. Henceforth we show that intracellular ATP delivery induces rapid healing of
incisional wounds via multiple mechanisms

Dr. Mary Saral.A has 30 years of experience in teaching and research in the field of Phytochemistry and pharmaceutical
chemistry. She is currently working as Dean & Professor in Chemistry. She Holds administrative responsibility as Dean of
School of Advanced Sciences, VIT Vellore since 2018 December till date. She Organized prestigious International Conference
ETC-2020 in association with Royal Society of Chemistry in which the Nobel Laurette in chemistry Prof.Robert H
Grubbs participated and delivered his Nobel Lecture.

The present pandemic which started in the year 2019 continues to impact the enrire globe affecting more than …. Million
of people and causing two million death todate.This makes the life on earth a big challenge inspite of various vacines have
been developed accorss the country.It is much more difficult to manage the post COVID-19 disease as more unpredictable
side effects and other related health issues are expected. To address this uncontrollable disease the enire world started
looking back curing through nature and with the products obtained from nature.This paper presents the evident based
practices in India in management of COVID -19 infections with the additional support from insilico studies.The natural
products summarised here can provide possible resistance to the novel coronavirus and can boost our immune system and
provide antiviral support to the numan

Dr. Prakash V Diwan, present responsibilities are Consultant at Indian Institute of Chemical Technology, Hyderabad and
Technical Advisor at Indian Pharmacopeia Commission, Govt.of India and Research Director at Central Research laboratory,
Belgaum , Karnataka. He served as a Director Grade Scientist at IICT, Hyderabad and Founder Director at NIPER,
Hyderabad and Director at School of Pharmacy, Hyderabad.

From Science Fiction to Reality: Nano medicine Brings Fresh Hope to the MedicalWorld. Nanomedicine is a offshoot of
nanotechnologies. Medical applications, dominate today's market, with sales of $19.1 billion. Emerging nano medicine technologies
could dramatically transform medical science today with their potential to address unmet medical needs and provide
targeted therapy. Nano medicine can offer impressive resolutions for various life threatening diseases including effective
drug delivery systems, drug discovery and development, medical diagnosis and devices. The advent of nanomedi
cine and techniques for the early diagnosis of diseases could usher in a new era of superior prophylactic or preventive
medicine. By using preventive medicine, treatment for diseases could be initiated even before preliminary symptoms
appear.
Medical Advantages
Nanotechnology has the potential to bring major advances in medicine.
• Nanobots could be sent into a patient's arteries to clear away blockages.
• Surgeries could become much faster and more accurate.
• Injuries could be repaired cell-by-cell.
• It may even become possible to heal genetic conditions by fixing the damaged genes. Cancer treatment,
Drug delivery, Drug development, Medical tools Diagnostic tests, Imaging
• Novel Drug Delivery Systemsof herbal drugs using nano technology: have a potential future
Nano medicine technology faces biggest challenges such as scalability . This perceived difficulty is attributed to the fact
that manufacturing standards for nanomaterials and components are yet to evolve. Therefore, there is an urgent need for
standardized manufacturing techniques; only then can nanotechnology become ubiquitous in everyday applications.
Furthermore, since the characteristics of nanoscale matter are very different owing to their unique nature, there is a need
for appropriate quality control measures. Concerns about the potential ill effects of engineered nanomaterials such as
nanotubes through inhalation, ingestion, or absorption through the skin are increasing. Challenges:
• The exact usage and quality of materials? strategy,
• Research is motivated by immediate profits, more concentration on commercial products,
• Are nanotechnology inventions required by the society?
• What about nano toxicity? Are products commercially viable?
In the longer term, perhaps 10–20 years from today, the earliest molecular machine systems and nanorobots may join the
medical armamentarium, finally giving physicians the most potent tools imaginable to conquer human disease, ill-health,
and aging.

Dr. Eugenia Belcastro is a biologist researcher in the Immuno-Infectivology, Pharmacotherapy and Clinical Trials Research
laboratory at the Children's Hospital Bambino Gesù Research Institute, Rome since 2021. She obtained a Master Degree
in Life Sciences applied to Biomedicine in 2013 at the University of Pisa and an international PhD in Life Sciences and Health and Genetics, Oncology and Clinical Medicine, under joint supervision between the University of Lorraine (France) and the University of Siena (Italy) in 2016. She covered
a postdoctoral researcher position at the Faculty of Pharmacy at the University of Strasbourg (INSERM UMR 1260,
Nanomédecine Régénérative) from May 2017 to August 2020. Her major research interests focused on cardiovascular
pharmacology and pathology, by studying the synergy between inflammation and oxidative stress, the pivotal role of the
endothelium in the control of vascular homeostasis in health and diseases such as diabetes, hypertension, senescence and
also in physiological ageing.

Endothelial senescence has been identified as an early event in the development of endothelial dysfunction, a hallmark
of cardiovascular disease. This study developed theranostic nanocarriers (NC) decorated with VCAM-1 antibodies
(NC-VCAM-1) in order to target cell surface VCAM-1, which is overexpressed in senescent endothelial cells (ECs) for diagnostic
and therapeutic purposes. Incubation of Ang II-induced premature senescent ECs or replicative senescent ECs with
NC-VCAM-1 loaded with lipophilic fluorescent dyes showed higher fluorescence signals than healthy EC, which was dependent
on the NC size and VCAM-1 antibodies concentration, and not observed following masking of VCAM-1. NC loaded
with omega 3 polyunsaturated fatty acid (NC-EPA:DHA 6:1) were more effective than native EPA:DHA 6:1 to prevent Ang
II-induced VCAM-1 and p53 upregulation, and SA-β-galactosidase activity in coronary artery segments. These theranostic
NC might be of interest to evaluate the extent and localization of endothelial senescence and to prevent pro-senescent
endothelial responses.

Dr. Doaa El-Bohy obtained her BSc (Clinical Pharmacy) from the Ain Shams University and her PhD (Clinical Pharmacy)
from Ain Shams University. She previously worked for MSA University with an academic record extended for 14 years’ experience
in academia. Her PhD research was based on the effect of different PPIs on the immunosuppressive medications
in renal transplantation patients. Her Area of interest is pharmacotherapy and nephrology either in ESKD, dialysis or
renal transplantation

Renal allograft survival requires multiple immunosuppressive drugs. This strategy may lead to gastric complications that
necessitate gastro-protective medications, notably, proton pump inhibitors (PPI). This study aimed to compare the influence
of pantoprazole and esomeprazole on serum cyclosporine trough levels (C0) in renal transplant recipients (RTR). A
prospective, parallel, open-label trial was conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain
trough concentrations of 100 to 150 μg/L, mycophenolate mofetil (MMF) 750 mg q12 hour and prednisolone at 5 mg daily
at Nasser Institute, Cairo, Egypt from January to September 2016. Patients were randomized into the esomeprazole group
(25) or pantoprazole group (22) receiving the same dose (40 mg once daily).
The study outcomes included clinical signs of rejection and renal function decline, assessed by elevations in serum creatinine,
caused by cyclosporine level variations in either of the two study groups. Renal function, C0 and CBC measurements
were measured at baseline and monthly for 6 months. The mean C0 values were higher in the pantoprazole group than
in the esomeprazole group in the sixth month only (P = .007). Serum creatinine level was lower in the sixth month than at
baseline in the esomeprazole group (P = .004). There were no signs of rejection biochemical or clinical in any of the study
groups. In conclusion, PPIs should be used with caution and doses should be titrated to reach the C0 targets in RTR, which
is of more importance in pantoprazole than esomeprazole to avoid C0 level elevation or decline affecting the allograft
function

Dr. P. Veeresh Babu received his Ph.D from Andhra University, Visakhapatnam, India. He worked at the Avanthi Institute
of Pharmaceutical Sciences for 4 years and since from 6 years he has been working at Gokaraju Rangaraju College of
Pharmacy, Hyderabad. He has 10 years of teaching and research experience. He has received Sri. J. J. Rao gold medal for
the best Ph.D thesis from Andhra University. He is the author of more than 25 peer-reviewed papers. He collaborates with
Pharmacology researchers of various Pharmaceutical industries and institutions on regular basis. His area of interest is
Electrophysiological studies, Receptor Pharmacology, Drug design and development, Biopharmaceutics and Pharmacokinetics
and Drug-drug, drug-herb and drug-food interaction studies.

Migraine is the most common disease, which can bring considerable burden to health care systems around the world. Its
symptoms include one side or bilateral headaches, often accompanied with nausea, vomiting or visual disturbances. It is
always accompanied with other neuropsychiatric disorders. One of the most common comorbidities is depression. Currently,
migraines and its comorbidities have some drug treatments, including non-specific and relatively specific medications.
But their applications are often accompanied with side-effects on gastrointestinal tract. Therefore, developing more effective
and safe interventions for migraine and its comorbidities is still a pressing task. Ayurveda is an alternative medicine
where herbal extracts and constituents are used for the management of various human ailments. The present study is an
attempt to investigate the anti-migraine and antidepressant activity of methanolic extract of leaves of Annona squamosa.
The antimigraine activity of the methanolic extract of leaves of Annona squamosa (MEAS) was evaluated by nitroglycerin
and acetic acid models whereas its antidepressant activity was screened by tail suspension and forced swimming tests.
Results showed that MEAS significantly reduced the NTG-induced migraine rats' behavioral indicators and acetic acid induced
writhings substantiating its anti-migraine activity. The significant reduction in immobility time in rats treated with
MEAS in the tail suspension and forced swimming tests is an evidence that the MEAS displays antidepressant activity.
The extract also prominently scavenged both the hydrogen peroxide and nitric oxide free radicals in in vitro models depicting
its antioxidant potential. Phytoconstituents like tannins, steroids, alkaloids, terpenoids and flavonoids present in
the extract might be responsible for its antimigraine, antidepressant and antioxidant activities. It is concluded that MEAS
could treat migraine and its common comorbidity depression providing an expecting treatment.

Malaria is an old disease and continues to be a major health problem in many countries. In spite of decrement in morbidity
and mortality due to malaria, the transmission is still active throughout the world. Hence, appropriate treatment is
needed to handle malaria in addition to preventive measures. However, unavailability of new drugs and the occurrence of
resistant Plasmodium strains toward many conventional antimalarial drugs including artemisinins are the major obstacles
in combating malaria infection. Thus, experts from all directions of our planet are in search of novel compounds, and many
new chemical entities, such as artefenomel, ferroquine, KAE609, KAF156, DSM265, methylene blue, MMV39048,
DDD107498, SJ733, and MMV253, have been under drug development process. While many agents are in the pipeline,
most of them are not able to kill both gametocytes and hypnozoites.

Dr. Mostafa Abbas Shalaby received his Ph.D. from Faculty of Veterinay Medicine, Cairo University, Egypt, since January
1980. He works at the Department of Pharmacology as a Professor and Previous Head of Pharmacology Department. He
supervised on 31 Master Theses and 19 PhD Theses. He published 100 scientific papers in local and international journals.
He attended 35 scientific conference as presenter, Keynote speaker and Chairman. He shared 12 scientific socities as a
membership. He was selected as an editorial board member for 10 International Journals. He won 3 prizes and awards
from Cairo Univesity. and Publons Peer Reviewer Award. He worked as peer reviewer of 66 manuscripts for 35 international
journals. He shared as a co-manager of 5 Research Projects at the Pharmacology Department, Faculty of Veterinary
Medicine and Faculty of Pharmacy, Cairo Unversity. He got a Scientific Peace Fellowship to USA at Pharmacology and
Toxicology, Department, Faculty of Veterinary Medicine, California University, Davis, USA.

Ginger roots are used as a poibular culinary spice and for medicinal purposes. The aim of this study was to assess some
pharmacological effects of ginger roots extract (GE) and its 6-Shogaol (6-SHO) compound in obese diabetic rat model.
Sixty mature rats were distributed into 6 groups (n=10). Group 1 was kept negative control and the other groups were fed
high-fat diet (HFD) for 4 weeks to induce obesity. The obese rats were rendered diabetic by daily subcutaneous injection
of alloxan (120 mg/kg) for 5 days. After induction of diabetes, group 2 was kept positive control (obese diabetic) and the
remaining 4 groups were orally given GE in 100 and 200 mg/kg and 6-SHO in 5 and 10 mg/kg daily for 6 weeks, respectively.
Blood samples were collected for biochemical analysis and livers were dissected out for preparing homogenates. GE
and its 6-SHO decreased body and fat weights and levels of aspartate aminotransferase (AST), alanine aminotransferase
enzymes (ALT), total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL). Blood glucose and leptin were
decreased, while insulin was increased in rats given GE and its 6-CHO. Activities of hepatic superoxide dismutase (SOD),
glutathione peroxidase (GPx) and catalase (CAT) antioxidant enzymes were enhanced. Conclusions: GE and its 6-SHO
produce anti-obesity, hepatoprotective, hypolipidemic, antidiabetic, and anti-oxidant effects. These effects may be attributed
to the presence of 6-SHO in ginger extract. This study suggests that intake of ginger roots as a drink may be beneficial
for obese patients who suffer from diabetes.

Dr. Ozan Emre Eyupoglu is an Assistant Professor in School of Pharmacy at Istanbul Medipol University, İstanbul, Turkey
He received his PhD Degree from Graduate School of Natural & Applied Sciences, Chemistry (Biochemistry), Karadeniz
Technical University, Turkey in 2017. His area of interest includes Health Sciences, Medicine, Basic Medical Sciences, Biochemistry,
Biophysics, Biomolecules, Proteomics and Biological Spectroscopy. He has published number of researches and
conference articles about the chromatographic analysis and antioxidant activities of medicinal plants in reputed journals.
He is closely related to topics such as nanobiotechnology, artificial intelligence, machine learning, and innovative techniques,
and plans studies for processing biochemical data for disease diagnosis. He is an interdisciplinary scientist who
specializes in developing on-line chromatographic methods. He supervised 2 Master degree candidates who are making
thesis on the coagulation system and aromatherapy recently. Nowadays, he has 4 doctorate students who work about nanotechnology
and controlled released, nutrigenetics, apitherapeutic toxicology, geriatric nutrition. He, who is an Associate
member of The European Materials Modeling Council, had International Young Scientist Award 2020 on Engineering, Science
and Medicine from VDGOOD Technology Factory.

Endoxifen, the active metabolite of tamoxifen, can be used in aqueous form as a good antitumor drug with its nanocarrier
[1]. Phenformin is a mitochondrial complex I inhibitor that induces bioenergetic stress [2]. In this study, herbal phenolic metabolites
are converted into nanotransferozomic forms and increase the mitochondrial energy of tumors with antidiabetic
drugs such as phenformin. Thus, uncontrolled growing tumors disappear unstable with their high energies. As a secondary
benefit, this extinction helps to activate the energy's immune cells and strengthens the metabolism. The contribution of
the vegetal mineral composition to these effects is more synergistic in unstable trace elements with vacant orbitals in their
final orbits in spite of antagonistic in others. Nano-phenolic metabolites with low zeta potential absorbed in the crystals,
which are the inner membrane folds of the mitochondria, are pumped into the intermembrane space and increase the
energy release by activating the ATP synthases. Increasing high energy leads to uncontrolled division of tumor cells, and
each cell that is destroyed leads to the birth of a new tumor-free cell. In the study, the plant phenolic acid components released
in a controlled manner from the nanocarrier transferosomes are converted into lipidomic products by using them
as energy fuel in the compartments of the mitochondrial biomolecule. The mapping of these lipidomic products by HPLC
analysis has been carried out successfully. The dyed photos of the lipidomic molecules of the mapped mitochondrial regions
were scanned with a 2D printer scanner and Image J analysis was performed.

Dr. Mrs.Akshada A.Koparde Currently working as Dean Academics, Associate Professor, Department of Pharmaceutical Chemistry, KIMSDTU’s Krishna Institute of Pharmacy, Karad (Maharashtra), India. She has obtained her Ph.D in Pharmacy from Shivaji University, Kolhapur, Completed M.Pharm from Appasaheb Birnale college of Pharmacy, Sangli, and completed B.Pharm from Government College of Pharmacy, Karad. She has written 2 book chapters, 3 books and published 23 research papers. She is life member of APTI. She has been recently awarded as Young researcher award in December 2020.

Since, from ancient times all over the world, doctors and patients are implementing the use of Herbal medicines because of its better therapeutics value and fewer side effects as compared to synthetic medicines. The future endeavors of the herbal medicines has came into existence from past, as chemist used ayurvedic plants being reported. Miraculous changes can be made in known or unknown ayurvedic medicinal plants and the future of the world can be dreamed for better health for tomorrow. Importance of herbal medinies is happening all over the world and more people are taking note of herbal therapies to treat diseases. In current COVID 19 pandemic situation, herbal therapies home remedies has played important role for building immunity. Thus taking into consideration, application of smart drug delivery in herbal medicines will help the common man and importance of value added herbal drug delivery will be imbibe on persons mind. Nature is the source and our world is blessed to have a vast knowledge base of Ayurveda whose potential is being realized in the recent years. However, If scientific and smart novel drug delivery technology is applied in herbal medicine, it may help in increasing the efficacy and reducing the side effects of various herbal compounds and herbs. To increase patient compliance and avoid repeated administration Phytotherapeutics as a scientific approach can be used to deliver the components in a sustained manner. This can be achieved by designing novel drug delivery systems (NDDS) for herbal constituents. This is the basic idea behind incorporating novel method of drug delivery in herbal medicines. Thus it is important to integrate novel drug delivery system and Indian Ayurvedic medicines to combat diseases. Modern phytopharmaceutical research can solve the scientific need such as determination of pharmacokinetics, mechanism of action, site of action, accurate dose required of herbal medicines to be incorporated in novel drug delivery system, such as nanoparticles, microemulsions, matrix systems, solid dispersions, liposomes, solid lipid nanoparticles and so on. Smart and novel approach is nanotechnology and carbon nanotube generation for site specific drug delivery. Herbal biomarkers integrated with known synthetic medinine are the newer smart approach for targeted drug delivery with use of herbal as well as synthetic medicines. Nano-sized drug delivery systems of herbal drugs have a potential future for enhancing the activity and overcoming problems associated with plant medicines. Hence, integration of the nanocarriers as a SDDS in the traditional medicine system is essential to conflict more chronic diseases like asthma, diabetes, cancer, rheumatism and others. SMART means Simple smooth, modern, attainable, reliable and targeted delivery of drugs that benefits the common man and world can be dreamed for better health for tomorrow. 

Prof. Raffaele Pezzani is both a biologist and a physician with a PhD in Neuroscience at the University of Padova, Italy.
He has over 60 scientific publications and he has been serving as an editorial board member and as an editor of reputed
impacted journals. He is the principal investigator of his research group in Padova, having a long lasting and significant
experience (more than 20 years) in phytotherapy, biology, endocrinology, medicine, nutraceutics.

Chios mastic gum is a natural product of the Mediterranean area derived from the dried resinous exudate of stems and
branches of the tree Pistacia lentiscus L. var. Chia. The resin has been traditionally used as food and beverages flavoring
additives, as an ingredient of cosmetics and in numerous health products since ancient Greek times. Several research
works have been published on the pharmacologic activities of Chios mastic gum. Antibacterial, antifungal, anti-inflammatory,
antioxidant, chemopreventive/cytotoxic, cardio and hepatoprotective, wound healing properties have been investigated
in different preclinical and clinical experiments. In addition, in 2015 the European Medicines Agency has deeply analyzed
the available literature on Chios mastic gum and reported that the resin as an herbal medicinal product could be
useful for mild dyspeptic disorders, symptomatic treatment of minor inflammations of the skin and for wound healing. We
summarize the available literature on Chios mastic gum with a special emphasis on the clinical works that justify (or
refute) its use in human disease